Mostrar el registro sencillo del ítem

dc.contributor.authorLozano-Ojalvo, Daniel
dc.contributor.authorCamara, Carmen
dc.contributor.authorLopez-Granados, Eduardo
dc.contributor.authorNozal, Pilar
dc.contributor.authorDel Pino-Molina, Lucía
dc.contributor.authorBravo-Gallego, Luz Yadira
dc.contributor.authorPaz-Artal, Estela
dc.contributor.authorPion, Marjorie
dc.contributor.authorCorrea-Rocha, Rafael
dc.contributor.authorOrtiz, Alberto
dc.contributor.authorLopez-Hoyos, Marcos
dc.contributor.authorIribarren, Marta Erro
dc.contributor.authorPortoles, Jose
dc.contributor.authorRojo-Portoles, Maria Pilar
dc.contributor.authorOjeda, Gloria 
dc.contributor.authorCervera Hernandez, Isabel 
dc.contributor.authorGonzalez-Perez, Maria 
dc.contributor.authorBodega-Mayor, Irene 
dc.contributor.authorMontes-Casado, Maria 
dc.contributor.authorPortoles, Pilar 
dc.contributor.authorPerez-Olmeda, Mayte 
dc.contributor.authorOteo-Iglesias, Jesus 
dc.contributor.authorSanchez-Tarjuelo, Rodrigo 
dc.contributor.authorPothula, Venu
dc.contributor.authorSchwarz, Megan
dc.contributor.authorBrahmachary, Manisha
dc.contributor.authorTan, Anthony Tanoto
dc.contributor.authorLe Bert, Nina
dc.contributor.authorBerin, Cecilia
dc.contributor.authorBertoletti, Antonio
dc.contributor.authorGuccione, Ernesto
dc.contributor.authorOchando, Jordi 
dc.date.accessioned2022-04-25T11:18:51Z
dc.date.available2022-04-25T11:18:51Z
dc.date.issued2021-08-24
dc.identifier.citationCell Rep. 2021;36(8):109570.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14165
dc.description.abstractThe rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.es_ES
dc.description.sponsorshipResearch reported in this publication was supported in part by the National Cancer Institute of the NIH (5R01HD102614-02; R01CA249204 and R01CA248984) and an ISMMS seed fund to E.G. The authors gratefully acknowledge use of the services and facilities of the Tisch Cancer Institute supported by a NCI Cancer Center Support Grant (P30 CA196521). M.S. was supported by a NCI training grant (T32CA078207). This work was supported by an ISMMS seed fund to J.O.; Instituto de Salud Carlos III (COV20-00668) to R.C.R.; the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181) co-financed by the European Development Regional Fund “A way to achieve Europe” to E.P.; the Instituto de Salud Carlos III, Spain (COV20/00170); the Government of Cantabria, Spain (2020UIC22-PUB-0019) to M.L.H.; the Instituto de Salud Carlos III (PI16CIII/00012) to P.P.; the Fondo Social Europeo e Iniciativa de Empleo Juvenil YEI (Grant PEJ2018-004557-A) to M.P.E.; and by REDInREN 016/009/009 ISCIII. This project has received funding from the European Union Horizon 2020 research and innovation programs VACCELERATE and INsTRuCT under grant agreements 101037867 and 860003.es_ES
dc.language.isoenges_ES
dc.publisherCell Press es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBNT162b2 vaccinees_ES
dc.subjectCOVID-19es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectT-cell immunityes_ES
dc.titleDifferential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individualses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID34390647es_ES
dc.format.volume36es_ES
dc.format.number8es_ES
dc.format.page109570es_ES
dc.identifier.doi10.1016/j.celrep.2021.109570es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderNIH - National Cancer Institute (NCI) (Estados Unidos) es_ES
dc.contributor.funderIcahn School of Medicine at Mount Sinai es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderGobierno de Cantabria (España) es_ES
dc.contributor.funderUnión Europea. Comisión Europea. H2020 es_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2211-1247es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.celrep.2021.109570es_ES
dc.identifier.journalCell Reportses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/101037867/EUes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/860003/EUes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20-00668es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20/00181es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI16CIII/00012es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PEJ2018-004557-Aes_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/REDInREN 016/009/009es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional